Dihydroergotamine ameliorates liver fibrosis by targeting transforming growth factor β type II receptor.
Zheng KX, Yuan SL, Dong M, Zhang HL, Jiang XX, Yan CL, Ye RC, Zhou HQ, Chen L, Jiang R, Cheng ZY, Zhang Z, Wang Q, Jin WZ, Xie W.
Zheng KX, et al. Among authors: zhang hl, zhang z.
World J Gastroenterol. 2023 May 28;29(20):3103-3118. doi: 10.3748/wjg.v29.i20.3103.
World J Gastroenterol. 2023.
PMID: 37346154
Free PMC article.